Rubicon Research Limited
All news and filings related to Rubicon Research Limited.
View all news & filings- Medium impact
Rubicon Research's Satara Facility Receives One Procedural Observation from US FDA Inspection
Rubicon Research's Satara facility underwent a US FDA inspection from Oct 5-9, 2026. A single procedural observation was issued, with no relation to data integrity. This marks a potential first successful unannounced inspection for the site and the third for the company in FY2026-27.
Read the summary - Low impact
Rubicon Research Ltd. Files SEBI Compliance Certificate for Q2 FY27
Rubicon Research Limited filed a compliance certificate for Q2 FY27 with SEBI. The certificate confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It was issued by MUFG Intime India Private Limited for the quarter ending September 30, 2026.
Read the summary - Low impact
Rubicon Research Allots 7,200 Equity Shares Under ESOP Scheme
Rubicon Research Limited allotted 7,200 equity shares on October 8, 2026, under its Employee Stock Option Scheme 2022. This increases the company's paid-up equity share capital to ₹16,55,39,108.
Read the summary - Low impact
Rubicon Research Limited: Trading Window Closed for Q2 FY27 Results
Rubicon Research Limited will close its trading window from October 1, 2026, for the declaration of unaudited financial results for Q2 FY27 and the half-year ending September 30, 2026. The window will reopen 48 hours post-announcement.
Read the summary - High impact
Rubicon Research Limited's 27th AGM: Key Resolutions Passed, Including Merger and ESOP Plan
Rubicon Research Limited's 27th AGM on August 26, 2026, approved financial statements, a final dividend, director re-appointment, and director remuneration. Key approvals included the ESOP 2026 plan and its extension to subsidiaries. A significant resolution was the merger of KIA Health Tech Private Limited with Rubicon Research Limited.
Read the summary - Medium impact
Rubicon Research Limited Holds 27th AGM on August 26, 2026
Rubicon Research Limited held its 27th AGM on August 26, 2026. Key agenda items included approving FY26 financial statements, a final dividend, and a merger scheme. The company also discussed its IPO milestone in FY25-26 and its evolution into a specialty products company, showcasing strong financial growth and expanded capabilities.
Read the summary - High impact
Rubicon Research Q1 FY27: Revenue up 51% to ₹534 Cr, PAT surges 96% to ₹85 Cr
Rubicon Research reported Q1 FY27 revenue of ₹534 crore, up 51% YoY, with PAT at ₹85 crore, up 96%. The Arinna acquisition contributed ₹12 crore to revenue. The company acquired a US manufacturing site for USD 2.9 million and revised its FY27 EBITDA margin guidance to 23%. Nitin Jajodia moves to Chief Commercial Officer; Rohit becomes CFO.
Read the summary - Low impact
Rubicon Research Limited Publishes Unaudited Financial Results
Rubicon Research Limited published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were announced in The Financial Express and Loksatta newspapers and will be available on the company's website.
Read the summary - Low impact
Rubicon Research Ltd Q1 FY27 Earnings Conference Call Audio Recording Released
Rubicon Research Limited released the audio recording of its earnings conference call for the quarter ended June 30, 2026. The recording is available on the company's website and was held on August 14, 2026.
Read the summary - Low impact
Rubicon Research IPO Proceeds Utilization: No Deviation Reported for Q1FY27
Rubicon Research Limited's Monitoring Agency Report for Q1FY27 confirms no deviation in IPO fund utilization. The IPO in Oct 2025 raised ₹5,000 million (₹500 crore) for debt prepayment and growth. Unutilized funds were ₹830.67 million (₹83.07 crore) as of June 30, 2026. The Board approved extending the utilization timeline to March 31, 2027.
Read the summary - Medium impact
Rubicon Research Appoints Rohit Saraogi as CFO, Extends Chairman Venkat Changavalli's Term
Rubicon Research appointed Rohit Saraogi as CFO-Designate and Senior Management Personnel, effective August 14, 2026. Current CFO Nitin Jajodia will move to CCO. Additionally, Venkat Changavalli's term as Chairman is extended from September 18, 2026, to June 10, 2027.
Read the summary - High impact
Rubicon Research Q1FY27 Net Profit Jumps to ₹824.49 Cr Standalone, ₹847.81 Cr Consolidated
Rubicon Research reported standalone Q1FY27 net profit of ₹824.49 Cr and consolidated net profit of ₹847.81 Cr. The company acquired an 85% stake in Arinna Lifesciences for ₹1,759.17 million. The timeline for utilizing IPO proceeds was extended to March 31, 2027. A scheme of amalgamation for Kia Health Tech was approved.
Read the summary - Low impact
Rubicon Research Schedules Earnings Conference Call for August 14, 2026
Rubicon Research Limited will hold an Earnings Conference Call on Friday, August 14, 2026, to discuss its financial performance for the quarter ended June 30, 2026. Senior management, including the CEO and CFO, will be present.
Read the summary - Low impact
Rubicon Research Announces 27th AGM and E-Voting Information
Rubicon Research Limited announced its 27th Annual General Meeting (AGM) will be held on August 4, 2026. The company has disseminated the AGM notice and Annual Report for FY 2025-26 via email and provided e-voting details to shareholders.
Read the summary - Low impact
Rubicon Research Limited Releases Business Responsibility and Sustainability Report for FY 2025-26
Rubicon Research Limited has released its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG initiatives, risk management strategies, and commitments to sustainable practices. It highlights efforts in corporate governance, innovation, employee development, and environmental stewardship, including targets for renewable energy and water neutrality.
Read the summary - Low impact
Rubicon Research Announces 27th AGM, Final Dividend, and Record Date via Newspaper Publication
Rubicon Research Limited published newspaper ads on July 30, 2026, announcing its 27th AGM via VC/OAVM. The ads detail e-voting, KYC updates, final dividend, and record date. This informs shareholders about key corporate actions.
Read the summary - Medium impact
Rubicon Research to Merge Wholly Owned Subsidiary Kia Health Tech
Rubicon Research Limited will merge its wholly owned subsidiary, Kia Health Tech Private Limited, with itself. The Board of Directors approved the scheme on July 20, 2026. This merger aims for business synergy and operational efficiencies. Regulatory approvals are pending. The Appointed Date is April 1, 2026.
Read the summary - High impact
Rubicon Research Acquires First US Manufacturing Facility for USD 2.9 Million
Rubicon Research acquired a US manufacturing facility in East Brunswick, NJ, for USD 2.9 million. The facility, taken over on July 21, 2026, will focus on specialty products. Manufacturing is expected to begin in 2027 after quality system implementation. CEO Parag Sancheti highlighted the strategic importance of US manufacturing.
Read the summary - Medium impact
Rubicon Research sets Aug 26 for 27th AGM; Aug 7 as Record Date for ₹1.50 dividend
Rubicon Research will hold its 27th AGM on August 26, 2026. The record date for a final dividend of ₹1.50 per share for FY26 is August 7, 2026. The company also approved the merger of its wholly-owned subsidiary, Kia Health Tech Private Limited, with Rubicon Research Limited, effective April 1, 2026.
Read the summary - Medium impact
Rubicon Research Ltd Board Approves AGM Date, Dividend Record Date, and Merger Scheme
Rubicon Research Ltd will hold its 27th AGM on August 26, 2026. The record date for the final dividend of ₹1.50 per share for FY26 is August 7, 2026. The Board also approved the merger scheme of its wholly owned subsidiary, Kia Health Tech Private Limited, with the company.
Read the summary - Low impact
Rubicon Research Limited Allots 1,49,158 Equity Shares Under ESOP Scheme
Rubicon Research Limited allotted 1,49,158 equity shares under its ESOP Scheme 2022 on July 20, 2026. This increases the company's paid-up equity share capital to ₹16,55,31,908.
Read the summary - Medium impact
Rubicon Research Facility Undergoes US FDA Inspection; Receives 2 Procedural Observations
Rubicon Research's Pithampur manufacturing facility was inspected by the US FDA from June 29 to July 3, 2026. The inspection resulted in two procedural observations on Form 483, with no data integrity issues. The company expects to ramp up commercial operations at this facility from Q1 2027.
Read the summary - Low impact
Rubicon Research Limited Closes Trading Window for Q1FY27 Financial Results
Rubicon Research Limited will close its trading window from July 1, 2026, for the declaration of unaudited financial results for the quarter and year ending June 30, 2026. The window will reopen 48 hours after results submission.
Read the summary - High impact
Rubicon Research Q4 FY26: Revenue Surges 44%, PAT Jumps 112% YoY
Rubicon Research reported Q4 FY26 revenue of ₹513.9 crore, up 44% YoY, and PAT of ₹76.8 crore, up 112% YoY. Full-year revenue grew 37% to ₹1754 crore. The company acquired an 85% stake in Arinna Lifesciences for ₹200 crore. A dividend of ₹1.5 per share was recommended.
Read the summary - Low impact
Rubicon Research Releases Audio Recording of Q4 FY26 Earnings Conference Call
Rubicon Research Limited has made the audio recording of its earnings conference call for the quarter and financial year ended March 31, 2026, available on its website. The call took place on May 30, 2026.
Read the summary - Low impact
Rubicon Research Publishes Audited FY26 Financial Results
Rubicon Research Limited's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, on May 29, 2026. The results are available on the company and stock exchange websites.
Read the summary - Low impact
Rubicon Research Limited Allots 2,90,626 Equity Shares Under ESOP 2022
Rubicon Research Limited allotted 2,90,626 equity shares on May 29, 2026, under its ESOP 2022. This increases the company's paid-up equity share capital to ₹16,53,82,750.
Read the summary - Medium impact
Rubicon Research Recommends Dividend, Reports Audited FY26 Results
Rubicon Research Limited announced audited financial results for FY26. The Board recommended a dividend of ₹1.50 per equity share for FY26, subject to member approval at the AGM. The company's auditors issued an unmodified opinion on the results.
Read the summary - Low impact
Rubicon Research Approves Employee Stock Option Scheme 2026
Rubicon Research Limited's Board approved the Employees Stock Option Scheme 2026. The scheme allows for the grant of 24,84,415 stock options, including 6,72,162 from the existing pool. The approval is pending member and regulatory clearances. The exercise price will be at least the face value of ₹1.
Read the summary - High impact
Rubicon Research Q4 FY26 Revenue Surges 43.5% YoY to ₹513.9 Crore, PAT Jumps 111.8%
Rubicon Research reported a 43.5% YoY revenue increase to ₹513.9 crore in Q4 FY26. PAT surged 111.8% YoY to ₹76.8 crore. Full-year revenue grew 36.6% to ₹1,754 crore, and PAT rose 83.6% to ₹246.7 crore. The company acquired Arinna Lifesciences for ₹176 crore and recommended a 150% dividend.
Read the summary - Medium impact
Rubicon Research Q4FY26 Results: Board Approves Audited Financials, Recommends Dividend
Rubicon Research Limited's Board approved audited standalone and consolidated financial results for FY26. The company recommended a final dividend of ₹1.50 per equity share for FY26, subject to shareholder approval at the upcoming AGM. Auditors issued an unmodified opinion on the financial results.
Read the summary - Low impact
Rubicon Research Schedules Earnings Conference Call for FY26 Results on May 29, 2026
Rubicon Research Limited will hold an earnings conference call on May 29, 2026, to discuss financial performance for the quarter and year ended March 31, 2026. Senior management, including the CEO and CFO, will participate.
Read the summary - Low impact
Rubicon Research Monitoring Agency Report for Q4 FY26: No Deviation in IPO Fund Utilization
Rubicon Research's Monitoring Agency Report for Q4 FY26 confirms no deviation in IPO fund utilization. Total IPO size was ₹13,775 million (₹1,377.5 crore). As of March 31, 2026, ₹3,351.45 million (₹335.15 crore) of IPO proceeds have been utilized, with ₹1,648.55 million (₹164.86 crore) unutilized. Unutilized funds are invested in FDs earning up to 7.05%.
Read the summary - Medium impact
Rubicon Research Completes 85% Stake Acquisition in Arinna Lifesciences
Rubicon Research Limited announced the completion of its acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. Arinna Lifesciences Limited is now a subsidiary of Rubicon Research.
Read the summary - Medium impact
Rubicon Research's Canadian R&D Facility Clears USFDA Inspection Without Issues
Rubicon Research's Canadian R&D facility was inspected by the USFDA from April 20-24, 2026. The inspection concluded without any Form-483 observations, indicating successful compliance with regulatory standards.
Read the summary - Medium impact
Rubicon Research Receives Income Tax Assessment Order for AY 2023-24
Rubicon Research received an Income Tax Assessment Order for AY 2023-24. Additions/disallowances total ₹20.68 crore due to ALP adjustments. A demand of ₹17.25 crore was raised, and penalty proceedings are being initiated. The company plans to appeal the order.
Read the summary - Medium impact
Rubicon Research to Acquire 85% Stake in Arinna Lifesciences for ₹175.92 Crore
Rubicon Research Limited will acquire an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 crore. Arinna, a pharmaceutical marketing company with ₹71.5 crore turnover in FY25, will become Rubicon's subsidiary. The deal aims to expand Rubicon's presence in the CNS therapeutic segment. Completion is expected within one month.
Read the summary - Low impact
Rubicon Research Files SEBI Compliance Certificate for Q4 FY26
Rubicon Research Limited submitted a compliance certificate for the quarter ended March 31, 2026. The certificate confirms adherence to SEBI (Depositories and Participants) Regulations, 2018, regarding the dematerialisation of securities processed by MUFG Intime India Private Limited.
Read the summary - Low impact
Rubicon Research Allots 3.4 Lakh Shares Under ESOP Scheme 2022
Rubicon Research Limited allotted 3,41,815 equity shares under its Employee Stock Option Scheme 2022 on March 31, 2026. This increases the company's paid-up equity share capital to ₹16,50,92,124.
Read the summary - Low impact
Rubicon Research Closes Trading Window for Audited Financial Results on April 1, 2026
Rubicon Research Limited will close its trading window from April 1, 2026, for the declaration of audited financial results for the quarter and year ending March 31, 2026. The window will reopen 48 hours post-results submission.
Read the summary - Medium impact
Rubicon Research Limited Shareholders Approve Director Appointment and Secretarial Auditor
Rubicon Research Limited shareholders approved the appointment of Dr. Pradnya Saravade as an Independent Woman Director and M/s. BNP & Associates as Secretarial Auditors. Both resolutions passed with a significant majority via remote e-voting, which concluded on 15th March 2026.
Read the summary - Low impact
Rubicon Research Limited Publishes Newspaper Advertisement for Postal Ballot Notice
Rubicon Research Limited published newspaper ads on Feb 14, 2026, for its Postal Ballot Notice. Advertisements appeared in Financial Express and Loksatta. This confirms dispatch of the notice to shareholders with required disclosures.
Read the summary - Low impact
Rubicon Research Limited Seeks Shareholder Approval for Director Appointment and Secretarial Auditor.
Rubicon Research Limited is seeking shareholder approval via postal ballot for appointing Dr. Pradnya Saravade as an Independent Woman Director and M/s. BNP & Associates as Secretarial Auditors. E-voting is open from February 14 to March 15, 2026, with results expected by March 17, 2026.
Read the summary - High impact
Rubicon Research Q3 FY26 Earnings Call Transcript Released
Rubicon Research reported Q3 FY26 revenue of ₹476 crore (up 52% YoY) and PAT of ₹73 crore (up 91% YoY). EBITDA was ₹112 crore (up 59% YoY). The Pithampur facility is expected to be operational by mid-2026, with commercialization in Q1 CY27. R&D productivity is improving, and the company maintains EBITDA margin guidance of 22-23%. Dr. Pradnya Saravade was appointed as an Independent Director.
Read the summary - Low impact
Rubicon Research Publishes Un-audited Financial Results for Q3 FY26
Rubicon Research Limited published its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results are available on the company website and via a QR code and weblink in newspaper publications.
Read the summary - Medium impact
Rubicon Research Appoints New Director, Approves Merger with Subsidiary, Appoints Secretarial Auditor
Rubicon Research appointed Dr. Pradnya Saravade as Additional Independent Woman Director and approved the merger of its wholly-owned subsidiary, KIA Health Tech, with the company. M/s. BNP & Associates was appointed as Secretarial Auditor. Mr. Anand Agarwal resigned as Non-Executive Director.
Read the summary - Medium impact
Rubicon Research Appoints Dr. Pradnya Saravade as Additional Director, Approves Merger Plan
Rubicon Research appointed Dr. Pradnya Saravade as an Additional Independent Woman Director for three years from Feb 3, 2026. Mr. Anand Agarwal resigned as Non-Executive Director. M/s. BNP & Associates was appointed Secretarial Auditor for FY26-FY30. The company also approved in-principle the merger of its subsidiary, KIA Health Tech, with Rubicon Research.
Read the summary - Medium impact
Rubicon Research: Board Approves Director Appointment, Merger In-Principle, and Secretarial Auditor
Rubicon Research appointed Dr. Pradnya Saravade as an Additional Independent Woman Director for three years. Mr. Anand Agarwal resigned as Non-Executive Director. M/s. BNP & Associates was appointed Secretarial Auditor for five years. The company also approved in-principle the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited.
Read the summary - Low impact
Rubicon Research IPO Proceeds Utilized as per Plan for Q3 FY26
Rubicon Research's Monitoring Agency Report for Q3 FY26 confirms IPO proceeds utilization aligns with objectives. ₹2,975 million utilized for debt prepayment, inorganic growth, and expenses. Unutilized ₹2,025 million deployed in FDs and accounts. No deviation from IPO objects noted.
Read the summary - Medium impact
Rubicon Research Board Approves Director Appointment, Secretarial Auditor, and Merger In-Principle
Rubicon Research appointed Dr. Pradnya Saravade as Additional-Independent Woman Director for three years. Mr. Anand Agarwal resigned as Non-Executive Director. M/s. BNP & Associates was approved as Secretarial Auditor for five years. In-principle approval was granted for merging wholly-owned subsidiary KIA Health Tech with Rubicon Research to achieve operational synergies.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio